The exploration of human erythrocytes (red blood cells) as biocompatible carriers for drug delivery offers promising advancements in targeted therapeutics. This study investigates the feasibility of utilizing erythrocytes as carriers for pravastatin, a commonly used statin for cholesterol management. In vitro methodologies were employed to load pravastatin into erythrocytes, followed by comprehensive characterization of the loading efficiency, encapsulation stability, and release profile. Erythrocyte morphology, membrane integrity, and hemoglobin release were monitored post-loading to assess potential cytotoxic effects. Findings indicate that erythrocytes effectively encapsulate pravastatin with high efficiency, maintain structural stability, and enable a controlled release over an extended period. The results highlight human erythrocytes as a potential drug delivery platform for pravastatin, potentially enhancing its bioavailability and reducing systemic side effects. Further research is needed to optimize loading protocols and confirm in vivo efficacy.

Erythrocytes, Red Blood Cells, Pravastatin

McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 2002; 87(4):1451-1458.

Moghadasian MH. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Life Sciences. 1999;65(13):1329-1337.

Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002; 41(5):343-370.

Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 2000; 39:397–412.

Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2004; 57(2):181-187.

Koitabashi Y, Kumai T, Matsumoto N, Watanabe M, Sekine S, Yanagida Y, Kobayashi S. Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects. Life Sciences. 2006; 78(24):2852-2859.

Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J. 2006; 151(2):273 - 281.

Oda S, Nagahama R, Nakano K, Matoba T, Kubo M, Sunagawa K, Tominaga R, Egashira K. Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia. JVS. 2010;52(2):412-420.

Kang B. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm. 2004; 274(1-2):65-73.

Charman WN, Chan HK, Finnin BC, Charman SA. Drug Delivery: A Key Factor in Realising the Full Therapeutic Potential of Drugs. Drug Dev Res. 1999;46:316-327.

Margulis-Goshen K, Magdassi S. Formation of simvastatin nanoparticles from microemulsion. Nanomedicine: NBM. 2009; 5(3):274-281.

Gupta A, Mishra AK, Bansal P, Kumar S, Gupta V, Singh R, Kalyan GS. Cell Based Drug Delivery System Through Resealed Erythrocyte- A Review. Int J Pharm. 2010; 2(1):23-30.

Shavi GV, Doijad RC, Deshpande PB, Manvi FV, Meka SR, Udupa N, Omprakash R, Dhirendra K. Erythrocytes as carrier for prednisolone: in vitro and in vivo evaluation. Pak J Pharm Sci. 2010; 23(2):194-200.

Gothoskar AV. Resealed Erythrocytes:A Review. J Pharm Technol. 2004;:140-158.